Impact of 89Zr-girentuximab PET/CT versus conventional imaging on clinical decision making in patients with indeterminate renal masses (ZIRCON-X)

The ZIRCON-X study evaluated whether adding ⁸⁹Zr-girentuximab PET/CT to standard imaging could influence clinical decision-making in patients with indeterminate renal masses suspicious for clear cell renal cell carcinoma. Results showed that nearly half of patients would have had a change in management, often a major one, suggesting this CAIX-targeted PET imaging may significantly improve diagnostic clarity and guide more appropriate treatment decisions.